Merus and Halozyme collaborate to advance subcutaneous Petosemtamab development
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
Conjugated Estrogens Tablets are indicated for moderate to severe menopausal symptoms, including hot flashes, and for the prevention of postmenopausal osteoporosis in women at significant risk
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
Diversifying its portfolio to include late-phase antiviral agent
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Fenebrutinib targets cells in the immune system known as B cells and microglia
OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue
Subscribe To Our Newsletter & Stay Updated